Category: BioTech

BioTech, Services Sector, Software

Sonic Beats on Q2 Earnings, In Line on Revenue

Sonic (NASDAQ:SONC) reported Q2 earnings of $0.07 per share, up from $0.05 per share last year and a penny better than the analyst consensus on Capital IQ. System-wide same-store sales increased 1.4%, consisting of an increase of 1.5% at franchise drive-ins and an increase of 1.3% at company drive-ins. Total revenue was $109.7 million, down from $111.1 million last year and about in line with … Continue reading Sonic Beats on Q2 Earnings, In Line on Revenue

Mark DeFrance
BioTech

Biotech Volatile Stocks: CytRx Corporation (NASDAQ:CYTR), Synta Pharmaceuticals (NASDAQ:SNTA), Idenix Pharmaceuticals (NASDAQ:IDIX), CEL-SCI Corporation (NYSEMKT:CVM)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation (NASDAQ:CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the “Class Period”). CytRx Corporation (NASDAQ:CYTR) stock performance was 0.00% in last session and finished the day … Continue reading Biotech Volatile Stocks: CytRx Corporation (NASDAQ:CYTR), Synta Pharmaceuticals (NASDAQ:SNTA), Idenix Pharmaceuticals (NASDAQ:IDIX), CEL-SCI Corporation (NYSEMKT:CVM)

John Bellich
BioTech

Biotech New Highs: BioSpecifics Technologies (NASDAQ:BSTC), Five Prime Therapeutics (NASDAQ:FPRX), IGI Laboratories (NYSEMKT:IG), Durata Therapeutics (NASDAQ:DRTX)

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 2.14% in last session and finished the day at $27.16. Traded volume was 61,391.00 shares in the last session and the average volume of the stock remained 27,510.00 shares. The beta of the stock remained 0.90. BioSpecifics Technologies Corp. … Continue reading Biotech New Highs: BioSpecifics Technologies (NASDAQ:BSTC), Five Prime Therapeutics (NASDAQ:FPRX), IGI Laboratories (NYSEMKT:IG), Durata Therapeutics (NASDAQ:DRTX)

Colin Pettis
BioTech

Biotech Losers: Egalet Corp (NASDAQ:EGLT), Marina Biotech (OTCMKTS:MRNA), Conatus Pharmaceuticals (NASDAQ:CNAT), Acceleron Pharma (NASDAQ:XLRN)

Egalet Corporation (NASDAQ:EGLT) announced that its fourth quarter and year ended December 31, 2013 financial results will be released on Wednesday, March 26, 2014. Egalet Corp (NASDAQ:EGLT) stock performance was -5.53% in last session and finished the day at $17.41. Traded volume was 82,789.00 shares in the last session and the average volume of the stock remained 196,859.00 shares. The beta of the stock remained … Continue reading Biotech Losers: Egalet Corp (NASDAQ:EGLT), Marina Biotech (OTCMKTS:MRNA), Conatus Pharmaceuticals (NASDAQ:CNAT), Acceleron Pharma (NASDAQ:XLRN)

Richard Atkins
BioTech

Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was 39.33% in last session and finished the day at … Continue reading Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

John Bellich
BioTech

Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

The iShares Biotechnology Indexhas fallen 2.46% in the last month of trading, and biotech stalwarts Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD ) are both down over 8%. What’s most surprising is that Celgene and Gilead are expected to have strong years in terms of earnings and the development of their respective clinical pipelines. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 0.53% in last session and … Continue reading Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

Mark DeFrance